Clinical trial
A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell…
NCT00129519 · Graceway Pharmaceuticals, LLC, Industry · Completed
Key facts
| NCT number | NCT00129519 |
|---|---|
| Title | A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence |
| Official title | Open-label Study to Evaluate the Use of Imiquimod 5% Cream for Reducing Postsurgical Recurrence or Persistence of Basal Cell Carcinoma Following Excision by Curettage |
| Lead sponsor | Graceway Pharmaceuticals, LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Basal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Imiquimod 5% cream |
| Enrollment | 63 |
| Start date | Jan 1, 2004 |
| Primary completion | Jan 1, 2006 |
| Completion | Jan 1, 2006 |
| First posted | Aug 12, 2005 |
| Last update posted | Jul 16, 2010 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: